Literature DB >> 9346174

Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.

M E Sherman1, S Sturgeon, L A Brinton, N Potischman, R J Kurman, M L Berman, R Mortel, L B Twiggs, R J Barrett, G D Wilbanks.   

Abstract

We performed a multi-institutional, incident case-control study of 328 endometrioid and 26 serous carcinomas to assess whether risk factors and circulating hormone levels in women with serous carcinoma differ from the expected profile for endometrial carcinoma We also evaluated exposures potentially related to endometrial cancer risk, anthropometric measurements, and circulating levels of sex hormones and related carrier proteins. Histopathologic specimens were reviewed without knowledge of the other data. As expected, a statistically significant association was observed for high body mass index (BMI) (relative risk, 3.5) and use of menopausal estrogens (relative risk, 2.4) in the endometrioid carcinoma cases, whereas serous carcinomas were not strongly associated with these factors. Smoking and oral contraceptive use decreased risk for both tumor types. For five of six sex hormones tested, age-adjusted mean serum levels in patients with serous carcinoma were significantly lower than those in women with endometrioid carcinoma. After adjustment for BMI, these differences were narrowed, but levels of albumin-bound estradiol and estrone remained significantly lower in the serous cases. Age and BMI-adjusted levels of sex hormone-binding globulin were significantly higher in patients with serous carcinoma than in women with endometrioid carcinomas. In conclusion, risk factors and sex hormone levels in patients with uterine serous carcinoma seem to differ from those in women with endometrioid carcinoma, suggesting that there may be at least two different pathways of endometrial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346174

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  33 in total

1.  Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.

Authors:  Veronica Wendy Setiawan; Jennifer A Doherty; Xiao-Ou Shu; Mohammad R Akbari; Chu Chen; Immaculata De Vivo; Angela Demichele; Montserrat Garcia-Closas; Marc T Goodman; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Pamela L Horn-Ross; James V Lacey; Loic Le Marchand; Douglas A Levine; Xiaolin Liang; Jolanta Lissowska; Galina Lurie; Monica McGrath; Steven A Narod; Timothy R Rebbeck; Giske Ursin; Noel S Weiss; Yong-Bing Xiang; Hannah P Yang; Wei Zheng; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

2.  Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Authors:  Ashley S Felix; David E Cohn; Theodore M Brasky; Richard Zaino; Kay Park; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Marcus E Randall; Louise A Brinton
Journal:  Am J Obstet Gynecol       Date:  2018-08-07       Impact factor: 8.661

Review 3.  [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].

Authors:  S Lax
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 4.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

5.  Relationships of uterine and ovarian tumors to pre-existing chronic conditions.

Authors:  Louise A Brinton; Lori C Sakoda; Kirsten Frederiksen; Mark E Sherman; Susanne K Kjaer; Barry I Graubard; Jorgen H Olsen; Lene Mellemkjaer
Journal:  Gynecol Oncol       Date:  2007-09-07       Impact factor: 5.482

6.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

7.  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:  Louise A Brinton; Ashley S Felix; D Scott McMeekin; William T Creasman; Mark E Sherman; David Mutch; David E Cohn; Joan L Walker; Richard G Moore; Levi S Downs; Robert A Soslow; Richard Zaino
Journal:  Gynecol Oncol       Date:  2013-02-26       Impact factor: 5.482

Review 8.  Endocrine disruptors in female reproductive tract development and carcinogenesis.

Authors:  Liang Ma
Journal:  Trends Endocrinol Metab       Date:  2009-08-25       Impact factor: 12.015

Review 9.  Aromatase expression and regulation in breast and endometrial cancer.

Authors:  Hong Zhao; Ling Zhou; Anna Junjie Shangguan; Serdar E Bulun
Journal:  J Mol Endocrinol       Date:  2016-04-11       Impact factor: 5.098

10.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.